Molecular Testing: How Can Oncologists Work Better With Pathologists?

Video

Dr. Aisner discusses some of the key ways oncologists can work better with pathologists at their institutions.

Dara Aisner, MD, PhD, assistant professor at the University of Colorado Anschutz Medical Campus, discusses some of the key things oncologists can do to work better with pathologists at their institutions.

Dr. Aisner also talks about some of the common points of miscommunication between oncologists and pathologists, and some instances in which oncologists might want second opinions on certain pathology tests results.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.
Other ongoing urothelial cancer trials are assessing enfortumab vedotin–based combinations in the neoadjuvant setting.
Given resource scarcity, developing practice strategies for resource-constrained settings would require aid from commercial and government stakeholders.
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Thomas Powles, MBBS, MRCP, MD, highlighted fatigue, nausea, and peripheral neuropathy as toxicities observed with enfortumab vedotin plus pembrolizumab.
Large international meetings may facilitate conversations regarding disparities of care outside of high-income countries.
Related Content